{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:31:51Z","timestamp":1773102711190,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T00:00:00Z","timestamp":1630108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Graefes Arch Clin Exp Ophthalmol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00417-021-05356-0","type":"journal-article","created":{"date-parts":[[2021,8,28]],"date-time":"2021-08-28T11:02:31Z","timestamp":1630148551000},"page":"353-361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["A comparative study between ciclosporine A eye drop (2%) and tacrolimus eye ointment (0.03%) in management of children with refractory vernal keratoconjunctivitis"],"prefix":"10.1007","volume":"260","author":[{"given":"Mohamed Amin","family":"Heikal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tarek T.","family":"Soliman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Walid Samir","family":"Abousaif","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Adel","family":"Shebl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,28]]},"reference":[{"key":"5356_CR1","doi-asserted-by":"crossref","unstructured":"Leonardi A, Motterle L, Bortolotti M (2008) Allergy and the eye. Clin Exp Immunol;153 Suppl 1:17\u201321.","DOI":"10.1111\/j.1365-2249.2008.03716.x"},{"issue":"6","key":"5356_CR2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3129\/i06-061","volume":"41","author":"A Kili\u00e7","year":"2006","unstructured":"Kili\u00e7 A, G\u00fcrler B (2006) Topical 2% cyclosporine A in preservative-free artificial tears for the treatment of vernal keratoconjunctivitis. Can J Ophthalmol 41(6):693\u2013698","journal-title":"Can J Ophthalmol"},{"key":"5356_CR3","first-page":"41","volume":"54","author":"B Zepeda-Ortega","year":"2007","unstructured":"Zepeda-Ortega B, Rosas-vargas MA, Ito Tsuchiya FM (2007) Conjuntivitis al\u00e9rgica en la infancia. Rev Alerg Mex 54:41\u201353","journal-title":"Rev Alerg Mex"},{"issue":"4","key":"5356_CR4","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/sj.eye.6700675","volume":"18","author":"S Bonini","year":"2004","unstructured":"Bonini S, Coassin M, Aronni S, Lambiase A (2004) Vernal keratoconjunctivitis. Eye (Lond) 18(4):345\u2013351","journal-title":"Eye (Lond)"},{"issue":"2","key":"5356_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1755-3768.2008.01347.x","volume":"87","author":"S Kumar","year":"2009","unstructured":"Kumar S (2009) Vernal keratoconjunctivitis: a major review. Acta Ophthalmol 87(2):133\u2013147","journal-title":"Acta Ophthalmol"},{"issue":"2","key":"5356_CR6","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2165\/00003495-199550020-00002","volume":"50","author":"M Hingorani","year":"1995","unstructured":"Hingorani M, Lightman S (1995) Therapeutic options in ocular allergic disease. Drugs 50(2):208\u2013221","journal-title":"Drugs"},{"key":"5356_CR7","doi-asserted-by":"crossref","unstructured":"Spadavecchia L, Fanelli P, Tesse R, Brunetti L, Cardinale F, Bellizzi M, Rizzo G, Procoli U, Bellizzi G, Armenio L (2006) Efficacy of 1.25% and 1% topical cyclosporine in the treatment of severe vernal keratoconjunctivitis in childhood. Pediatr Allergy Immunol;17(7) 527\u2013532.","DOI":"10.1111\/j.1399-3038.2006.00427.x"},{"issue":"2 Suppl 2","key":"5356_CR8","first-page":"644","volume":"20","author":"D BenEzra","year":"1988","unstructured":"BenEzra D, Matamoros N, Cohen E (1988) Treatment of severe vernal keratoconjunctivitis with cyclosporine A eyedrops. Transplant Proc 20(2 Suppl 2):644\u2013649","journal-title":"Transplant Proc"},{"key":"5356_CR9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1159\/000050876","volume":"215","author":"A Avunduk","year":"2001","unstructured":"Avunduk A, M, Avunduk M, C, Erd\u00f6l H, Kapicioglu Z, Akyol N, (2001) Cyclosporine effects on clinical findings and impression cytology specimens in severe vernal keratoconjunctivitis. Ophthalmologica 215:290\u2013293","journal-title":"Ophthalmologica"},{"key":"5356_CR10","doi-asserted-by":"crossref","unstructured":"Ryu EH, Kim JM, Laddha PM, Chung ES, Chung TY(2012) Therapeutic effect of 0.03% tacrolimus ointment for ocular graft versus host disease and vernal keratoconjunctivitis. Korean J Ophthalmol;26(4):241\u20137.","DOI":"10.3341\/kjo.2012.26.4.241"},{"issue":"11","key":"5356_CR11","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1097\/ICO.0000000000000918","volume":"35","author":"S Chatterjee","year":"2016","unstructured":"Chatterjee S, Agrawal D (2016) Tacrolimus in corticosteroid-refractory vernal keratoconjunctivitis. Cornea 35(11):1444\u20131448","journal-title":"Cornea"},{"key":"5356_CR12","doi-asserted-by":"crossref","unstructured":"Akpek EK, Dart JK, Watson S, Christen W, Dursun D, Yoo S, O'Brien TP, Schein OD, Gottsch JD (2004) A randomized trial of topical cyclosporin 0.05% in topical steroid-resistant atopic keratoconjunctivitis. Ophthalmology;111(3):476\u201382.","DOI":"10.1016\/j.ophtha.2003.05.035"},{"issue":"6 Pt 1","key":"5356_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0181-5512(04)96181-5","volume":"27","author":"F Chast","year":"2004","unstructured":"Chast F, Lemare F, Legeais JM, Batista R, Bardin C, Renard G (2004) Pr\u00e9paration d\u2019un collyre de ciclosporine \u00e0 2% [Cyclosporine 2% eye drops preparation]. J Fr Ophtalmol 27(6 Pt 1):567\u2013576","journal-title":"J Fr Ophtalmol"},{"issue":"1","key":"5356_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/jop.1996.12.1","volume":"12","author":"RG Fiscella","year":"1996","unstructured":"Fiscella RG, Le H, Lam TT, Labib S (1996) Stability of cyclosporine 1% in artificial tears. J Ocul Pharmacol Ther 12(1):1\u20134","journal-title":"J Ocul Pharmacol Ther"},{"key":"5356_CR15","unstructured":"Tacliment ointment 0.03% w\/w (2019) Aurolab india company: www.aurolab.com\/tacliment_cp.asp.pdf. Accessed July 2021."},{"key":"5356_CR16","doi-asserted-by":"crossref","unstructured":"Secchi AG, Tognon MS, Leonardi A (1990) Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis. Am J Ophthalmol; 15;110(6):641\u20135.","DOI":"10.1016\/S0002-9394(14)77061-8"},{"issue":"11","key":"5356_CR17","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1016\/S0161-6420(91)32069-4","volume":"98","author":"JH Bleik","year":"1991","unstructured":"Bleik JH, Tabbara KF (1991) Topical cyclosporine in vernal keratoconjunctivitis. Ophthalmology 98(11):1679\u20131684","journal-title":"Ophthalmology"},{"issue":"3","key":"5356_CR18","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/S1081-1206(10)61958-8","volume":"89","author":"N Pucci","year":"2002","unstructured":"Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R, Campa L, Vierucci A (2002) Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 89(3):298\u2013303","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"4","key":"5356_CR19","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1136\/bjo.2005.082461","volume":"90","author":"M Daniell","year":"2006","unstructured":"Daniell M, Constantinou M, Vu HT, Taylor HR (2006) Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol 90(4):461\u2013464","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"5356_CR20","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1136\/bjo.2005.070888","volume":"89","author":"S Tatlipinar","year":"2005","unstructured":"Tatlipinar S, Akpek EK (2005) Topical ciclosporin in the treatment of ocular surface disorders. Br J Ophthalmol 89(10):1363\u20131367","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"5356_CR21","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1136\/bjophthalmol-2011-300415","volume":"96","author":"S De Smedt","year":"2012","unstructured":"De Smedt S, Nkurikiye J, Fonteyne Y, Tuft S, De Bacquer D, Gilbert C, Kestelyn P (2012) Topical ciclosporin in the treatment of vernal keratoconjunctivitis in Rwanda, Central Africa: a prospective, randomised, double-masked, controlled clinical trial. Br J Ophthalmol 96(3):323\u2013328","journal-title":"Br J Ophthalmol"},{"key":"5356_CR22","doi-asserted-by":"crossref","unstructured":"Y\u00fccel OE, Ulus ND (2016) Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis. Singapore Med J;57 (9):507\u201310","DOI":"10.11622\/smedj.2015161"},{"key":"5356_CR23","unstructured":"Labcharoenwongs P, Jirapongsananuruk O, Visitsunthorn N, Kosrirukvongs P, Saengin P, Vichyanond P (2012) A double-masked comparison of 0.1% tacrolimus ointment and 2% cyclosporine eye drops in the treatment of vernal keratoconjunctivitis in children. Asian Pac J Allergy Immunol;30 (3):177\u201384."},{"key":"5356_CR24","doi-asserted-by":"crossref","unstructured":"Wan Q, Tang J, Han Y, Wang D, Ye H (2018) Therapeutic effect of 0.1% tacrolimus eye drops in the tarsal form of vernal keratoconjunctivitis. Ophthalmic Res;59 (3):126\u2013134.","DOI":"10.1159\/000478704"},{"key":"5356_CR25","doi-asserted-by":"crossref","unstructured":"Kheirkhah A, Zavareh MK, Farzbod F, Mahbod M, Behrouz MJ (2011) Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis. Eye (Lond);25 (7):872\u201380","DOI":"10.1038\/eye.2011.75"},{"key":"5356_CR26","doi-asserted-by":"crossref","unstructured":"Kymionis GD, Kankariya VP, Kontadakis GA (2012) Tacrolimus ointment 0.03% for treatment of refractory childhood phlyctenular keratoconjunctivitis. Cornea;31 (8):950\u20132.","DOI":"10.1097\/ICO.0b013e318243f69d"},{"key":"5356_CR27","doi-asserted-by":"crossref","unstructured":"Ohashi Y, Ebihara N, Fujishima H, Fukushima A, Kumagai N, Nakagawa Y, Namba K, Okamoto S, Shoji J, Takamura E, Hayashi K (2010) A randomized, placebo-controlled clinical trial of tacrolimus ophthalmic suspension 0.1% in severe allergic conjunctivitis. J Ocul Pharmacol Ther. 26 (2) 165\u201374","DOI":"10.1089\/jop.2009.0087"},{"key":"5356_CR28","doi-asserted-by":"crossref","unstructured":"Fukushima A, Ohashi Y, Ebihara N, Uchio E, Okamoto S, Kumagai N, Shoji J, Takamura E, Nakagawa Y, Namba K, Fujishima H, Miyazaki D (2014) Therapeutic effects of 0.1% tacrolimus eye drops for refractory allergic ocular diseases with proliferative lesion or corneal involvement. Br J Ophthalmol;98 (8):1023\u20137","DOI":"10.1136\/bjophthalmol-2013-304453"}],"container-title":["Graefe's Archive for Clinical and Experimental Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05356-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00417-021-05356-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00417-021-05356-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T14:27:45Z","timestamp":1642516065000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00417-021-05356-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,28]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["5356"],"URL":"https:\/\/doi.org\/10.1007\/s00417-021-05356-0","relation":{},"ISSN":["0721-832X","1435-702X"],"issn-type":[{"value":"0721-832X","type":"print"},{"value":"1435-702X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,28]]},"assertion":[{"value":"6 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The Institutional Review Board (IRB) and Research Ethics Committee of Ophthalmic Department, Benha University, approved the study)5\/2019). The study adhered strictly to the tenets of the Declaration of Helsinki (2013 revision).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All subjects (patients and their parents) provided informed written consent for participation.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}